Clinical Trials on Refractory Adult Acute Myeloid Leukemia

Total 6480 results

National Cancer Institute (NCI)

Completed

Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Previously Treated Myelodysplastic Syndromes | Refractory Anemia With Excess Blasts | Refractory Anemia With Excess Blasts in Transformation

United States
Juan C. Ramos, MD

Withdrawn

Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias

Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Refractory Leukemia | Adult T-Cell Leukemia/Lymphoma | Relapsed Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Secondary Acute Myeloid Leukemia | Childhood Acute Myeloid Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 and other conditions

United States
German AML Cooperative Group

Unknown

Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic

Relapsed Acute Promyelocytic Leukemia | Refractory Acute Promyelocytic Leukemia

Germany
Masonic Cancer Center, University of Minnesota

Completed

Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML

Relapsed Acute Myelogenous Leukemia | Refractory Acute Myelogenous Leukemia

United States
University of Leipzig

Completed

Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a (AML2004)

Acute Myeloid Leukaemia

Germany
University of Sydney
Melbourne Health; Royal Brisbane and Women's Hospital

Unknown

Chemotherapy Followed by Infusion of Partially HLA Matched Unrelated Donor Cells for Patients With AML Who Are Ineligible for Stem Cell Transplantation (SCRAMBLE)

Acute Myeloid Leukaemia

Australia
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); Karyopharm Therapeutics Inc

Not yet recruiting

Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Relapsed Myelodysplastic Syndrome

United States
Actinium Pharmaceuticals

Recruiting

Venetoclax and Lintuzumab-Ac225 in AML Patients

Acute Myeloid Leukemia | Relapsed Adult AML

United States
Hematology department of the 920th hospital

Recruiting

Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid Leukemia

Refractory/Relapse Acute Myeloid Leukemia

China
Actinium Pharmaceuticals

Withdrawn

Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients

Acute Myeloid Leukemia | Relapsed Adult AML
Elucida Oncology
Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL)

Withdrawn

ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML (Pediatric AML)

Acute Myeloid Leukemia | AML, Childhood | Relapsed Pediatric AML | Refractory Pediatric AML
Verastem, Inc.

Withdrawn

Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia

Relapsed or Refractory Acute Myeloid Leukemia | Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
GlaxoSmithKline

Terminated

A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)

Leukaemia, Myelocytic, Acute

United States, Australia, Canada
First Affiliated Hospital Xi'an Jiaotong University

Not yet recruiting

Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML

Refractory Acute Myeloid Leukemia | Conditioning | Hematopoietic Stem Cell Transplantation | Relapse Leukemia
French Innovative Leukemia Organisation
Acute Leukemia French Association

Not yet recruiting

OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia

AML, Adult

France
The First Affiliated Hospital of Soochow University

Not yet recruiting

Investigation of the Gut Microbiota in Acute Myeloid Leukemia Receiving Two Different Induction Therapies

Infections | Acute Myeloid Leukemia | Gut Microbiota | Adult

China
City of Hope Medical Center
National Cancer Institute (NCI)

Not yet recruiting

Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Myelodysplastic Syndrome/Acute Myeloid Leukemia

United States
Chinese PLA General Hospital
Navy General Hospital, Beijing

Unknown

Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation

Recurrent Adult Acute Myeloid Leukemia

China
Federal Research Institute of Pediatric Hematology...

Unknown

Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias

Refractory Acute Myeloid Leukemia | Refractory Acute Lymphoblastic Leukemia

Russian Federation
MacroGenics

No longer available

Flotetuzumab Expanded Access Program

Acute Myeloid Leukemia | AML | AML, Adult Recurrent
AvenCell Europe GmbH
Allucent (NL) BV

Recruiting

Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

Germany, Netherlands
National Cancer Institute (NCI)

Not yet recruiting

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory High Risk Myelodysplastic Syndrome
Wake Forest University Health Sciences
National Cancer Institute (NCI); Cornerstone Pharmaceuticals

Not yet recruiting

CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory | Granulocytic Sarcoma

United States
M.D. Anderson Cancer Center

Active, not recruiting

Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Recurrent Acute Biphenotypic Leukemia | Refractory Acute Biphenotypic Leukemia

United States
M.D. Anderson Cancer Center

Active, not recruiting

Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Recruiting

Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

Refractory Acute Myeloid Leukemia | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Persistent Disease

United States
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia

Relapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid Leukemia | Relapsed or Refractory Non-Hodgkin Lymphoma | Relapsed or Refractory Chronic Lymphocytic Leukemia

United Kingdom, Spain, France, Australia
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions

United States
Great Ormond Street Hospital for Children NHS Foundation...
Wellcome Trust

Recruiting

Base Edited CAR T Cells Against AML: Deep Conditioning Ahead of Allogeneic Stem Cell Transplantation (CARAML)

Relapsed Acute Myeloid Leukaemia

United Kingdom
Nanfang Hospital of Southern Medical University
Shenzhen Second People's Hospital; Peking University Shenzhen Hospital; The Seventh... and other collaborators

Completed

Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML

Refractory Acute Myeloid Leukemia | Relapsed Acute Erythroid Leukemia | Salvage Treatment | HVA Regimen

China
Mendus

Completed

Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) | Leukemic Dendritic Cell Vaccination

Netherlands
University of Birmingham
Assistance Publique - Hôpitaux de Paris; Pfizer; Cancer Research UK; National Cancer...

Recruiting

International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia (Myechild01)

Acute Myeloid Leukaemia

France, Switzerland, United Kingdom, New Zealand, Australia, Ireland
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Suspended

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Hematopoietic and Lymphoid Cell Neoplasm | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | Recurrent Acute Lymphoblastic... and other conditions

United States
M.D. Anderson Cancer Center
Oncoceutics, Inc.

Recruiting

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia

United States
Istituto Scientifico Romagnolo per lo Studio e...
Charite University, Berlin, Germany; University of Bologna; Hannover Medical... and other collaborators

Not yet recruiting

Master Framework For Relapse or Refractory Acute Myeloid Leukemia (IMPACT STREAM)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

Italy
Washington University School of Medicine
Wugen, Inc.

Withdrawn

Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS

Myelodysplastic Syndromes | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Personalized NK Cell Therapy in CBT

Recurrent Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Myelodysplastic Syndrome... and other conditions

United States
University of Jena
Ludwig-Maximilians - University of Munich

Terminated

Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia, Adult

Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome

United States
University of Washington
National Cancer Institute (NCI)

Completed

Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Adult Acute Myeloid Leukemia | Adult Myelodysplastic Syndrome

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Suspended

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | Recurrent Acute Lymphoblastic... and other conditions

United States
National Cancer Institute (NCI)
Children's Oncology Group

Completed

Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome

United States
Lai Corporation Pty. Ltd.

Unknown

The Effects of AMPC in the Treatments of Refractory or Relapsed AML (AMPCAL)

Acute Myeloid Leukaemia Recurrent

Thailand
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Acute Myeloid Leukemia Post Cytotoxic Therapy

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Active, not recruiting

Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome

United States
Vanderbilt-Ingram Cancer Center
Astex Pharmaceuticals, Inc.; Forma Therapeutics, Inc.

Withdrawn

ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome
Brian Druker
AbbVie; Oregon Health and Science University; Incyte Corporation

Active, not recruiting

Ruxolitinib and Venetoclax in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States

Clinical Trials on Refractory Adult Acute Myeloid Leukemia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations